Boehringer Ingelheim, Terns, Viking may join market
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk…
Jim Cramer’s 4 stock ideas from JPMorgan Healthcare Conference
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from…
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s…
Apple longtime directors Al Gore and James Bell retiring from board
Former Vice President Al Gore speaks during the Agriculture Innovation Mission (AIM) for Climate Summit at the JW Marriott on May 08, 2023 in Washington, DC. Chip Somodevilla | Getty…
Oprah’s flip on weight loss drugs is a sign of what’s to come for the ‘Ozempic trade’ in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo…
Pharma had a year full of firsts
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The…
Amgen, Sunnova, Arvinas and more
Check out the companies making headlines before the bell. Sunnova — Shares of the residential and commercial solar company jumped 5.1% after Piper Sandler upgraded the solar name to overweight…
2024 expectations for Wegovy, Ozempic, Zepbound
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed…
Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to…
Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain…